Clinical Trials Logo

Respiratory Acidosis clinical trials

View clinical trials related to Respiratory Acidosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03503214 Completed - Acid-Base Imbalance Clinical Trials

Non Carbonic Buffer Power of Critical Ill Patients With Sepsis

Start date: March 7, 2018
Phase:
Study type: Observational

Alterations of acid-base equilibrium are very common in critically ill patients and understanding their pathophysiology can be important to improve clinical treatment. The human organism is protected against acid-base disorders by several compensatory mechanisms that minimize pH variations in case of blood variations in carbon dioxide content. The aim of the present study is to quantify the buffer power, i.e. the capacity to limit pH variations in response to carbon dioxide changes, in critically ill septic patients and compare these results with data collected from healthy volunteers.

NCT ID: NCT02612415 Completed - Hypoxia Clinical Trials

FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC) Feasibility Study

FIRST-ABC
Start date: November 2015
Phase: Phase 2/Phase 3
Study type: Interventional

A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill children

NCT ID: NCT01913977 Completed - Clinical trials for Respiratory Acidosis

Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System

Start date: February 20, 2014
Phase: N/A
Study type: Interventional

This prospective study includes 5 patients with ARDS (Acute Respiratory Distress Syndrome) treated by mechanical ventilation. In case of respiratory acidosis, extracorporeal CO2 (carbon dioxide)removal might be necessary. We hereby work with the Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy). The patients (M/V) are older than 18, not pregnant, have a BMI<30, and no contraindication for anticoagulation therapy. Under standard conditions patients are treated with a blood flow of QB=300mL/min and a gas flow (100% 02) of QG=7L/min. Blood sampling is performed from the arterial bloodline in the patients at 0, 1h, 3h, 24h, 48h, 72h, 96h, and 120h. A parameter study is also performed to optimise CO2 removal. Herewith, blood samples (1mL) are taken from the inlet and outlet line of the Lilliput2 at the previously mentioned time points and for different flow setting: Blood flow (QB) 200-300-400mL/min and gas flow (QG) 1.5, 3, 6, 7, 8L/min Blood samples are analysed for the different blood gases from which the extraction in the CO2 remover can be calculated for each setting of QB (blood flow) and QG (gas flow).